Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: Perspectives on positive allosteric modulation as a therapeutic approach

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 3, 2015, Pages 187-200

  Grupe, Morten ^a   Grunnet, Morten ^a,b   Bastlund, Jesper Frank ^a   Jensen, Anders A ^b  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2 HYDROXYETHYL) 1 PIPERAZINEETHANESULFONIC ACID; ATROPINE; CHOLINERGIC RECEPTOR; DESFORMYLFLUSTRABROMINE; DEXMECAMYLAMINE; ESTRADIOL; GALANTAMINE; LY 2087101; MECAMYLAMINE; NEUROTRANSMITTER; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; NS 206; NS 9283; PHYSOSTIGMINE; RECEPTOR SUBUNIT; SCOPOLAMINE; TEBANICLINE; UNCLASSIFIED DRUG; VARENICLINE; ZINC ION; LIGAND; NICOTINIC RECEPTOR;

ALLOSTERISM; ALZHEIMER DISEASE; BINDING SITE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLINERGIC TRANSMISSION; COGNITION; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; MOLECULAR BIOLOGY; NERVE CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; STOICHIOMETRY; SYNAPTIC TRANSMISSION; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; DRUG EFFECTS; METABOLISM;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; HUMANS; LIGANDS; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION;

EID: 84922714998     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12361     Document Type: Review

References (106)

1. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009;8:733-50.
2. Sarter M, Lustig C, Taylor SF. Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology 2012;62:1544-53.
3. Haydar SN, Dunlop J. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. Curr Top Med Chem 2010;10:144-52.
4. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007;74:1212-23.
5. Miyamoto S, Jarskog LF, Fleischhacker WW. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry 2013;26:158-65.
6. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7.
7. Bertrand D, Gopalakrishnan M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 2007;74:1155-63.
8. Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007;47:699-729.
9. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 2006;27:482-91.
10. Brown RW, Collins AC, Lindstrom JM, Whiteaker P. Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers. J Neurochem 2007;103:204-15.
11. Mao D, Perry DC, Yasuda RP, Wolfe BB, Kellar KJ. The alpha4beta2alpha5 nicotinic cholinergic receptor in rat brain is resistant to up-regulation by nicotine in vivo. J Neurochem 2008;104:446-56.
12. Giniatullin R, Nistri A, Yakel JL. Desensitization of nicotinic ACh receptors: shaping cholinergic signaling. Trends Neurosci 2005;28:371-8.
13. Nelson ME, Kuryatov A, Choi CH, Zhou Y, Lindstrom J. Alternate stoichiometries of 42 nicotinic acetylcholine receptors. Mol Pharmacol 2003;63:332-41.
14. Grupe M, Jensen AA, Ahring PK, Christensen JK, Grunnet M. Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (alpha4)3(beta2)2 nicotinic ACh receptors. Br J Pharmacol 2013;168:2000-10.
15. Timmermann DB, Sandager-Nielsen K, Dyhring T, Smith M, Jacobsen AM, Nielsen EO et al. Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of alpha2- and alpha4-containing nicotinic acetylcholine receptors. Br J Pharmacol 2012;167:164-82.
16. 2+ permeability of the (α4)3(β2)2 stoichiometry greatly exceeds that of (α4)2(β2)3 human acetylcholine receptors. Mol Pharmacol 2007;71:769-76.
17. Harpsøe K, Ahring PK, Christensen JK, Jensen ML, Peters D, Balle T. Unraveling the high- and low-sensitivity agonist responses of nicotinic acetylcholine receptors. J Neurosci 2011;31:10759-66.
18. Mazzaferro S, Benallegue N, Carbone A, Gasparri F, Vijayan R, Biggin PC et al. Additional acetylcholine (ACh) binding site at alpha4/alpha4 interface of (alpha4beta2)2alpha4 nicotinic receptor influences agonist sensitivity. J Biol Chem 2011;286:31043-54.
19. Eaton JB, Lucero LM, Stratton H, Chang Y, Cooper JF, Lindstrom JM et al. The unique alpha4+/-alpha4 agonist binding site in (alpha4)3(beta2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (alpha4)2(beta2)3 subtype. J Pharmacol Exp Ther 2014;348:46-58.
20. Mazzaferro S, Gasparri F, New K, Alcaino C, Faundez M, Iturriaga Vasquez P et al. Non-equivalent ligand selectivity of agonist sites in (alpha4beta2)2alpha4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy. J Biol Chem 2014;289:21795-806.
21. Olsen JA, Ahring PK, Kastrup JS, Gajhede M, Balle T. Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at alpha4beta2 nicotinic acetylcholine receptors. J Biol Chem 2014;289:24911-21.
22. Benallegue N, Mazzaferro S, Alcaino C, Bermudez I. The additional Acetylcholine binding site at the alpha4(+)/alpha4(-) interface of the (alpha4beta2) alpha4 nicotinic acetylcholine receptor Contributes to desensitisation. Br J Pharmacol 2013;170:304-16.
23. Marks MJ, Meinerz NM, Brown RW, Collins AC. 86Rb+ efflux mediated by α4β2*-nicotinic acetylcholine receptors with high and low-sensitivity to stimulation by acetylcholine display similar agonist-induced desensitization. Biochem Pharmacol 2010;80:1238-51.
24. Campling BG, Kuryatov A, Lindstrom J. Acute activation, desensitization and smoldering activation of human acetylcholine receptors. PLoS One 2013;8:e79653.
25. Henny P, Jones BE. Projections from basal forebrain to prefrontal cortex comprise cholinergic, GABAergic and glutamatergic inputs to pyramidal cells or interneurons. Eur J Neuorsci 2008;27:654-70.
26. Woolf NJ, Butcher LL. Cholinergic systems mediate action from movement to higher consciousness. Behav Brain Res 2011;221:488-98.
27. Levin ED. Complex relationships of nicotinic receptor actions, and cognitive functions. Biochem Pharmacol 2013;86:1145-52.
28. Hasselmo ME, Sarter M. Modes and models of forebrain cholinergic neuromodulation of cognition. Neuropsychopharmacology 2011;36:52-73.
29. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 2006;184:523-39.
30. Howe WM, Ji J, Parikh V, Williams S, Mocaer E, Trocme-Thibierge C et al. Enhancement of attentional performance by selective stimulation of α4β2(*) nAChRs: underlying cholinergic mechanisms. Neuropsychopharmacology 2010;35:1391-401.
31. Howe WM, Berry AS, Francois J, Gilmour G, Carp JM, Tricklebank M et al. Prefrontal cholinergic mechanisms instigating shifts from monitoring for cues to cue-guided performance: converging electrochemical and fMRI evidence from rats and humans. J Neurosci 2013;33:8742-52.
32. Bain EE, Robieson W, Pritchett Y, Garimella T, Abi-Saab W, Apostol G et al. A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD. Neuropsychopharmacology 2013;38:405-13.
33. Apostol G, Abi-Saab W, Kratochvil CJ, Adler LA, Robieson WZ, Gault LM et al. Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study. Psychopharmacology 2012;219:715-25.
34. Guillem K, Bloem B, Poorthuis RB, Loos M, Smit AB, Maskos U et al. Nicotinic acetylcholine receptor β2 subunits in the medial prefrontal cortex control attention. Science 2011;333:888-91.
35. Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 2004;10:147-66.
36. Decker MW, Bannon AW, Curzon P, Gunther KL, Brioni JD, Holladay MW et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J Pharmacol Exp Ther 1997;283:247-58.
37. Bancroft A, Levin ED. Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. Neuropharmacology 2000;39:2770-8.
38. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 1999;18:1235-44.
39. Lena C, Changeux JP, Mulle C. Evidence for "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci 1993;13:2680-8.
40. Zappettini S, Grilli M, Salamone A, Fedele E, Marchi M. Pre-synaptic nicotinic receptors evoke endogenous glutamate and aspartate release from hippocampal synaptosomes by way of distinct coupling mechanisms. Br J Pharmacol 2010;161:1161-71.
41. McClure-Begley TD, King NM, Collins AC, Stitzel JA, Wehner JM, Butt CM. Acetylcholine-stimulated [3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes. Mol Pharmacol 2009;75:918-26.
42. Anderson DJ, Malysz J, Gronlien JH, El Kouhen R, Hakerud M, Wetterstrand C et al. Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity 42 subunit combination. Biochem Pharmacol 2009;78:844-51.
43. Matsubayashi H, Amano T, Seki T, Sasa M, Sakai N. Postsynaptic alpha 4 beta 2 and alpha 7 type nicotinic acetylcholine receptors contribute to the local and endogenous acetylcholine-mediated synaptic transmissions in nigral dopaminergic neurons. Brain Res 2004;1005:1-8.
44. Chen Y, Sharples TJ, Phillips KG, Benedetti G, Broad LM, Zwart R et al. The nicotinic alpha 4 beta 2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology 2003;45:334-44.
45. Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 2001;86:3043-55.
46. Ge S, Dani JA. Nicotinic acetylcholine receptors at glutamate synapses facilitate long-term depression or potentiation. J Neurosci 2005;25:6084-91.
47. Kuffler SW, Yoshikami D. The number of transmitter molecules in a quantum: an estimate from iontophoretic application of acetylcholine at the neuromuscular synapse. J Physiol 1975;251:465-82.
48. Sarter M, Parikh V, Howe WM. Phasic acetylcholine release and the volume transmission hypothesis: time to move on. Nat Rev Neurosci 2009;10:383-90.
49. Lendvai B, Vizi ES. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiol Rev 2008;88:333-49.
50. Yamasaki M, Matsui M, Watanabe M. Preferential localization of muscarinic M1 receptor on dendritic shaft and spine of cortical pyramidal cells and its anatomical evidence for volume transmission. J Neurosci 2010;30:4408-18.
51. Grupe M, Paolone G, Jensen AA, Sandager-Nielsen K, Sarter M, Grunnet M. Selective potentiation of (alpha4)3(beta2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats. Biochem Pharmacol 2013;86:1487-96.
52. Aracri P, Amadeo A, Pasini ME, Fascio U, Becchetti A. Regulation of glutamate release by heteromeric nicotinic receptors in layer V of the secondary motor region (Fr2) in the dorsomedial shoulder of prefrontal cortex in mouse. Synapse 2013;67:338-57.
53. Rode F, Munro G, Holst D, Nielsen EO, Troelsen KB, Timmermann DB et al. Positive allosteric modulation of α4β2 nAChR agonist induced behaviour. Brain Res 2012;1458:67-75.
54. d'Incamps BL, Ascher P. Subunit composition and kinetics of the Renshaw cell heteromeric nicotinic receptors. Biochem Pharmacol 2013;86:1114-21.
55. Gotti C, Moretti M, Meinerz NM, Clementi F, Gaimarri A, Collins AC et al. Partial deletion of the nicotinic cholinergic receptor α4 or β2 subunit genes changes the acetylcholine sensitivity of receptor-mediated 86Rb+ efflux in cortex and thalamus and alters relative expression of α4 and β2 subunits. Mol Pharmacol 2008;73:1796-807.
56. Timmermann DB, Gronlien JH, Kohlhaas KL, Nielsen EO, Dam E, Jorgensen TD et al. An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 2007;323:294-307.
57. Coggan JS, Bartol TM, Esquenazi E, Stiles JR, Lamont S, Martone ME et al. Evidence for ectopic neurotransmission at a neuronal synapse. Science 2005;309:446-51.
58. Jones IW, Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J Neurosci 2004;24:11244-52.
59. Perez XA, Bordia T, McIntosh JM, Quik M. α6β2* and α4β2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol Pharmacol 2010;78:971-80.
60. Mantione E, Micheloni S, Alcaino C, New K, Mazzaferro S, Bermudez I. Allosteric modulators of alpha4beta2 nicotinic acetylcholine receptors: a new direction for antidepressant drug discovery. Future Med Chem 2012;4:2217-30.
61. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR et al. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha 4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995;11:201-3.
62. O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ et al. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 2007;78:356-62.
63. Lamb PW, Melton MA, Yakel JL. Inhibition of neuronal nicotinic acetylcholine receptor channels expressed in Xenopus oocytes by beta-amyloid1-42 peptide. J Mol Neurosci 2005;27:13-21.
64. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-14.
65. McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer's disease. Br J Clin Pharmacol 1999;48:471-80.
66. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007;28:316-25.
67. Kroker KS, Rast G, Rosenbrock H. Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP. Eur J Pharmacol 2011;671:26-32.
68. Paradiso K, Zhang J, Steinbach JH. The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid. J Neurosci 2001;21:6561-8.
69. Curtis L, Buisson B, Bertrand S, Bertrand D. Potentiation of human alpha4beta2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharmacol 2002;61:127-35.
70. Smulders CJ, Zwart R, Bermudez I, van Kleef RG, Groot-Kormelink PJ, Vijverberg HP. Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol 2005;509:97-108.
71. Pandya A, Yakel JL. Allosteric modulator Desformylflustrabromine relieves the inhibition of alpha2beta2 and alpha4beta2 nicotinic acetylcholine receptors by beta-amyloid(1-42) peptide. J Mol Neurosci 2011;45:42-7.
72. Sala F, Mulet J, Reddy KP, Bernal JA, Wikman P, Valor LM et al. Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite. Neurosci Lett 2005;373:144-9.
73. Weltzin MM, Schulte MK. Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with α4β2 neuronal nicotinic acetylcholine receptor orthosteric ligands. J Pharmacol Exp Ther 2010;334:917-26.
74. Kim JS, Padnya A, Weltzin M, Edmonds BW, Schulte MK, Glennon RA. Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator. Bioorg Med Chem Lett 2007;17:4855-60.
75. Liu X. Positive allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. Psychopharmacology 2013;230:203-13.
76. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-36.
77. Lopes C, Pereira EF, Wu HQ, Purushottamachar P, Njar V, Schwarcz R et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J Pharmacol Exp Ther 2007;322:48-58.
78. Kuryatov A, Onksen J, Lindstrom J. Roles of accessory subunits in alpha4beta2(*) nicotinic receptors. Mol Pharmacol 2008;74:132-43.
79. Weltzin MM, Huang Y, Schulte MK. Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES. Eur J Pharmacol 2012;732:159-68.
80. Broad LM, Zwart R, Pearson KH, Lee M, Wallace L, McPhie GI et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 2006;318:1108-17.
81. de Filippi G, Mogg AJ, Phillips KG, Zwart R, Sher E, Chen Y. The subtype-selective nicotinic acetylcholine receptor positive allosteric potentiator 2087101 differentially facilitates neurotransmission in the brain. Eur J Pharmacol 2010;643:218-24.
82. Olsen JA, Kastrup JS, Peters D, Gajhede M, Balle T, Ahring PK. Two distinct allosteric binding sites at alpha4beta2 nicotinic acetylcholine receptors revealed by NS206 and NS9283 give unique insights to binding activity-associated linkage at Cys-loop receptors. J Biol Chem 2013;288:35997-6006.
83. Lee CH, Zhu C, Malysz J, Campbell T, Shaughnessy T, Honore P et al. α4β2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of α4β2 nAChR agonists in pain. Biochem Pharmacol 2011;82:959-66.
84. Jin Z, Khan P, Shin Y, Wang J, Lin L, Cameron MD et al. Synthesis and activity of substituted heteroaromatics as positive allosteric modulators for alpha4beta2alpha5 nicotinic acetylcholine receptors. Bioorg Med Chem Lett 2014;24:674-8.
85. Grupe M, Grunnet M, Laursen B, Bastlund JF. Neuropharmacological modulation of the P3-like event-related potential in a rat two-tone auditory discrimination task with modafinil and NS9283, a positive allosteric modulator of alpha4beta2 nAChRs. Neuropharmacology 2014;79:444-55.
86. Mohler EG, Franklin SR, Rueter LE. Discriminative-stimulus effects of NS9283, a nicotinic alpha4beta2* positive allosteric modulator, in nicotine-discriminating rats. Psychopharmacology 2013;231:67-74.
87. Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P et al. Potentiation of analgesic efficacy but not side effects: co-administration of an alpha4beta2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochem Pharmacol 2011;82:967-76.
88. van den Beukel I, van Kleef RG, Zwart R, Oortgiesen M. Physostigmine and acetylcholine differentially activate nicotinic receptor subpopulations in Locusta migratoria neurons. Brain Res 1998;789:263-73.
89. Fedorov NB, Benson LC, Graef J, Lippiello PM, Bencherif M. Differential pharmacologies of mecamylamine enantiomers: positive allosteric modulation and noncompetitive inhibition. J Pharmacol Exp Ther 2009;328:525-32.
90. Hsiao B, Mihalak KB, Magleby KL, Luetje CW. Zinc potentiates neuronal nicotinic receptors by increasing burst duration. J Neurophysiol 2008;99:999-1007.
91. 2+ potentiation. J Neurosci 2008;28:6884-94.
92. Bianchi MT, Macdonald RL. Agonist trapping by GABAA receptor channels. J Neurosci 2001;21:9083-91.
93. Hansen SB, Taylor P. Galanthamine and non-competitive inhibitor binding to ACh-binding protein: evidence for a binding site on non-alpha-subunit interfaces of heteromeric neuronal nicotinic receptors. J Mol Biol 2007;369:895-901.
94. Young GT, Zwart R, Walker AS, Sher E, Millar NS. Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 2008;105:14686-91.
95. Pandya AA, Yakel JL. Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies. Biochem Pharmacol 2013;86:1054-62.
96. Howe WM, Sarter M. Prefrontal glutamatergic-cholinergic interactions for attention: glutamatergic coding of salience as a function of performance levels. In: Westerink BHC, Clinckers R, Smolders S, Sarre E, Michotte Y (eds). Monitoring molecules in neuroscience. Vrije Universiteit Brussels, Brussels, 2010; 57-9.
97. Parikh V, Man K, Decker MW, Sarter M. Glutamatergic contributions to nicotinic acetylcholine receptor agonist-evoked cholinergic transients in the prefrontal cortex. J Neurosci 2008;28:3769-80.
98. Dani JA, Ji D, Zhou FM. Synaptic plasticity and nicotine addiction. Neuron 2001;31:349-52.
99. Sarter M, Lustig C, Howe WM, Gritton H, Berry AS. Deterministic functions of cortical acetylcholine. Eur J Neuorsci 2014;39:1912-20.
100. Callahan PM, Hutchings EJ, Kille NJ, Chapman JM, Terry AV Jr. Positive allosteric modulator of alpha 7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 2013;67:201-12.
101. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 2012;62:1099-110.
102. Williams DK, Wang J, Papke RL. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem Pharmacol 2011;82:915-30.
103. Rose JE, Mukhin AG, Lokitz SJ, Turkington TG, Herskovic J, Behm FM et al. Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. Proc Natl Acad Sci USA 2010;107:5190-5.
104. Bastlund JF, Berry D, Watson WP. Pharmacological and histological characterisation of nicotine-kindled seizures in mice. Neuropharmacology 2005;48:975-83.
105. Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple timescales. Neuron 2007;56:141-54.
106. Katz B, Thesleff S. A study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol 1957;138:63-80.